Hypothetical reasons of the HIV1-AIDS 'tritherapy' failure. A challenging model

Biomedicine and Pharmacotherapy

Volumn 51, Issue 10, 1997, Pages 413-416

  Mathe G ^a  

^a Hopital Suisse de Paris   (France)

Author keywords

AIDS; HIV; Treatment failure; Tritherapy

Indexed keywords

ACRIFLAVINE; ELLIPTICINE DERIVATIVE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS LOAD; BIOLOGICAL MODEL; CLASSIFICATION; DRUG COMBINATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; TREATMENT FAILURE;

EID: 0031282880     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(97)82318-9     Document Type: Editorial

References (39)

1. Nau JY. Les experts préconisent une trithérapie immédiate chez les personnes infectées par le virus du SIDA. Le comité Dormont s'interroge sur la prescription des traitements en urgence. Le Monde 9 October 1997 :11
2. Autran B, Carcelain G, Li TS. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112
3. Collier AC, Coombs RW, Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996;334:1011
4. D'Aquila RT, Hughes MD, Johnson VD et al. Neviparine, zidovudine and didanosine compared with zidovudine, and didanosine in patients with HIV, infection : a randomized, double-blind, placebo controlled trial. Ann Intern Med 1996;124:1019
5. Jonas M. Infections à VIH : les essais de trithérapie donnent des résultats encourageants. Quotidien du Médecin 1996;5780:10
6. Nau JY. Les associations de lutte contre le SIDA s'inquiètent de la progression des résistances aux trithérapies. Le Monde 18 September 1997:8
7. Action-traitement, Act Up Paris, Aides, Arcat-SIDA, Nova Dona, Sida Info, Solidarité Enfants SIDA, Vaincre le SIDA
8. 1 infection and genome drug resistance. Lancet 1997;350:970
9. Stolberg SG. SIDA, un bémol sur les trithérapies. Courrier International 1997;358:35
10. Cohen J. The daunting challenge of keeping HIV supressed. Science 1997;277:32
11. Wider J. Randomising means, not aims in clinical trials. Lancet 1994;343:359
12. Hesse H. Glasperlenspiel gesammelte werke vol 9. Frankfurt: Suhrkamp, 1970
13. Lurie P, Wolfe S. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 1997;337:853-6
14. Nau JY. Arrêt des expériences américaines utilisant des placebos contre le SIDA en Afrique. Le Monde 26-27 October 1997:4
15. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117
16. Clarysse A, Kenis Y, Mathé G. Cancer Chemotherapy. New York : Springer, 1976
17. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5:137
18. Eron JJ, Chaw YK, Caliendo AM et al. Pol mutation conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother 1993;37:1480
19. Mathé G, Pontiggia P, Bourut C et al. In vivo eradication of Friend virus as an experimental HIV-model, by combination of zidovudine, acriflavine and an ellipticine analogue. Possible application to the treatment of human pre-AIDS. Biomed Pharmacother 1994;48:51
20. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphadenopathy virus-associated virus (HTLV-III/LAV) by 2' .3-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911
21. Mathé G, Chenu E, Bourut C et al. Amino-acridines action of Friend's retrovirus in relation to their molecular ionization. Biomed Pharmacother 1989;43:235
22. Mathé G, Pontiggia P. A screening model of anti-HIV non AZT cross resistance virostatics. Biomed Pharmacother 1993;47:461
23. Mathé G, Chenu E, Bourut C et al. The in vivo effect of ellipticine analogues on the blood concentration of Friend's virus : a murine model for studying anti-HIV drugs. Biomed Pharmacother 1993;47:457
24. Mathé G, Hallard M, Pontiggia P. Lymphangiography study of pelvic adenotherapy regression in phase II trial of methyl-hydroxy-ellipticine in HIV 1-AIDS complex. Biomed Pharmacother 1996;50:510
25. Fosse P, René B, Le Bret M et al. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res 1991;19:2861
26. Davies RH, Williams H, Smith HJ. Intermolecular forces and stereospecificity in drug action. In : Introduction to the Principal of Drug Design. London : Wright, 1988
27. Mathé G, Pontiggia P, Orbach-Arbouys S. Aids therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts : a phase I trial equivalent, concerning five virostatics. Biomed Pharmacother 1996;50:220
28. Mathé G, Colasanté U, Morette C et al. Will killing the last HIV 1 particle cure AIDS patients? II : Second part. Decrease of VL and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy ? Biomed Pharmacother 1996;50:473
29. Executive summary : dideoxyinosine/dideoxycytidine CPCRA study. Community Programs for Clinical Research on AIDS. Bethesda, MD, January 15, 1993
30. Larder BA, Kemp SA, Harrigan PRI. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-699
31. Pavia AT, Gather J, BMS-019 study group investigators, Grosso R, Dunkle LM, Cross AP, Mohanty S, Messina M, Smaldone L. Clinical efficacy of stavudine (d4T, Zerit compared to zidovudine (ZDV, Retrovir® in ZDV-pretreated HIV positive patients. The Proceedings of 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 17-20 1995
32. Kitchen VS, Skinner C, Arigoshi K et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5
33. Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV 1 protease. European Australian Collaborative Ritonavir Group. N Engl J Med 1995;333: 1528-33
34. Vacca JP, Dorsey BD, Schleif WA et al. L-735, 524 : an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;91:4096-100
35. Mathé G, Morette C, Hallard M et al. Combinations of three and four HIV 1 virostatics applied in short sequences differing from each other by drug rotation. I-Result of the viral load and on the CD4 number of a preliminary trial. Biomed Pharmacother 1997;51:
36. Mathé G, GvH or autologous GvH-like in HIV 1-AIDS complex pathophysiology ? New directions in blood cell and bone marrow transplants. Milwaukee, WI, September 13, 1997
37. Kuritzkes DR. Development of resistances to lamivudine (3TC) in NUCA 3001, a phase II comparative trial of 3TC versus 3TC+2DV. Second national conference on human retroviruses and related infections (Abstracts). Washington, 1995
38. Mathé G, Halle-Pannenko O, Bourut C. Active immunotherapy of AkR mice spontaneous leukemia Europ J Blin Biol Res 1972;17:900
39. Mathé G, Amiel JL, Friend C. Essai de traitement de la leucemie de Charlotte Friend par la greffe de cellules hématopoietiques de donneurs isogéniques vaccinés contre le virus. Bull Cancer 1962:49-416